Home > Insider Trading > Filing (0001562180-21-000345)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1590877	Regenxbio Inc.	RGNX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1346164	Curran Simpson	C/O Regenxbio Inc. 9600 Blackwell Road, Suite 210 Rockville MD 20850	Chief Oper. & Tech. Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-12	1,700	$19.50	19,448	No	4	M	Direct
Common Stock	Disposition	2021-01-12	1,700	$50.03	17,748	No	4	S	Direct
Common Stock	Acquisiton	2021-01-14	1,240	$19.50	18,988	No	4	M	Direct
Common Stock	Acquisiton	2021-01-14	10,372	$35.80	29,360	No	4	M	Direct
Common Stock	Disposition	2021-01-14	11,612	$50.01	17,748	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-12	1,700	$0.00	1,700	$19.50
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-14	1,240	$0.00	1,240	$19.50
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-14	10,372	$0.00	10,372	$35.80

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,240	2027-01-03	No	4	M	Direct
0	2027-01-03	No	4	M	Direct
17,128	2028-01-03	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $50.00 to $50.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vested in equal monthly installments over the 36 months thereafter.
The previously granted option, representing a right to purchase a total of 55,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2019, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.